Trials / Terminated
TerminatedNCT01588951
Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the trial is to compare the two-year relapse-free survival (RFS) of patients with acute myeloid leukemia (AML), presumed to be at high risk for relapse due to the presence of leukemia stem cells (LSCs) in their bone marrow at first complete remission (CR1), who receive either standard cytarabine-based chemotherapy or allogeneic stem cell transplantation (SCT).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cytarabine consolidation | Cytarabine-based consolidation per institutional standards. |
| DRUG | Allogeneic transplant | Allogeneic stem cell transplant per institutional standards. |
Timeline
- Start date
- 2013-12-01
- Primary completion
- 2017-04-01
- Completion
- 2017-04-01
- First posted
- 2012-05-01
- Last updated
- 2018-08-14
- Results posted
- 2017-06-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01588951. Inclusion in this directory is not an endorsement.